[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100084203":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":11,"centralContacts":16,"locations":21,"responsibleParty":35,"collaborators":10,"id":37,"slug":10,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":10,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"National Institutes of Health Clinical Center (CC)","NIH",[8],{"label":9,"type":10,"description":9,"interventionNames":10},"Dyslipidemia",null,[12],{"name":13,"affiliation":14,"role":15},"Robert D Shamburek, M.D.","National Heart, Lung, and Blood Institute (NHLBI)","PRINCIPAL_INVESTIGATOR",[17],{"name":13,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","(301) 496-3460","bobs@mail.nih.gov",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":10},"National Institutes of Health Clinical Center","RECRUITING","Bethesda","Maryland","20892","United States",{"type":30,"coordinates":31},"Point",[32,33],-77.10026,38.98067,{"lat":33,"lon":32},{"type":36,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100084203",false,"NCT00353782","Causes and Natural History of Dyslipidemias","Disease Pathogenesis and Natural History of Lipid Disorders","* INCLUSION CRITERIA:\n* Children \\>= 2 years of age and \\>12 kg and adults\n* Dyslipidemia subjects of interest the group\n\nThe following is a representative list of the types of patient presentations with dyslipidemia and potential diagnoses eligible for this protocol:\n\n* Plasma cholesterol levels \\>200 mg\u002Fdl or \\\u003C120 mg\u002Fdl includes patients with diagnoses such as familial hypercholesterolemia, familial combined hyperlipidemia, sitosterolemia, lipoprotein lipase, hepatic lipase or apo-CII deficiency, and dysbetalipoproteinemia.\n* Plasma LDL-C levels \\>130 mg\u002Fdl or \\\u003C70 mg\u002Fdl includes patients with diagnoses such as familial hypercholesterolemia, PCSK9, apo3500, familial combined hyperlipidemia, sitosterolemia, dysbetalipoproteinemia, abetalipoproteinemia and hypobetalipoproteinemia.\n* Plasma HDL-C levels \\>70 mg\u002Fdl or \\\u003C25 mg\u002Fdl includes patients with deficiency of cholesteryl ester transfer protein, lecithin cholesterol acyltransferase, phospholipid transfer protein, lipoprotein lipase, hepatic lipase, or apo-CII, ANGPTL3, and Tangier disease.\n* Plasma triglyceride levels \\>150 mg\u002Fdl includes patients with deficiency of lipoprotein lipase, hepatic lipase or apoC-II, GPIHBP1, LMF1, dysbetalipoproteinemia, Type I, Type IV and Type V hyperlipidemia.","ALL","2 Years","100 Years",{"count":47,"type":48},2000,"ESTIMATED","OBSERVATIONAL","This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the blood in particles called lipoproteins. These particles are involved in causing blood vessel diseases that can lead to conditions like atherosclerosis (hardening of the arteries) or heart attack. Participants will undergo accepted medical tests and procedures to evaluate their condition. Most of the test results are helpful in making a diagnosis and in guiding treatment.\n\nPeople with lipid disorders are eligible for this study. Representative types of patients include those with:\n\n* Plasma cholesterol levels greater than 200 mg\u002Fdl or less than 120 mg\u002Fdl\n* Plasma LDL-C levels greater than 130 mg\u002Fdl or less than 70 mg\u002Fdl\n* Plasma HDL-C levels greater than 70 mg\u002Fdl or less than 25 mg\u002Fdl\n* Unusual cholesterol deposits or xanthomas (nodules of lipid deposits on the skin)\n\nChildren under 2 years of age are excluded from the study.\n\nParticipants will undergo some or all of the following procedures:\n\n\\- Plasma evaluation. Apolipoproteins (plasma proteins involved in metabolism of cholesterol, triglycerides, phospholipids, and proteins in the blood) and enzymes involved in lipid metabolism are measured....",[52,53],"Hypercholesterolemia","Atherosclerosis",[55,56,57,58,59,60],"Triglyceride","Phospholipids","Free and Esterfied Cholesterol","Polydisperse","Lipoprotein Transport System","Natural History","2026-06-27",{"date":63,"type":64},"2026-06-30","ACTUAL",{"date":66,"type":64},"2003-10-14",{"name":14,"class":6},1]